TAKEDA PHARMACEUTIC-SP ADR (TAK) Fundamental Analysis & Valuation

NYSE:TAK • US8740602052

Current stock price

17.91 USD
-0.15 (-0.83%)
At close:
17.92 USD
+0.01 (+0.06%)
After Hours:

This TAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. TAK Profitability Analysis

1.1 Basic Checks

  • TAK had positive earnings in the past year.
  • TAK had a positive operating cash flow in the past year.
  • In the past 5 years TAK has always been profitable.
  • In the past 5 years TAK always reported a positive cash flow from operatings.
TAK Yearly Net Income VS EBIT VS OCF VS FCFTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B 1T

1.2 Ratios

  • TAK has a better Return On Assets (0.73%) than 80.31% of its industry peers.
  • TAK has a better Return On Equity (1.48%) than 82.38% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 2.32%, TAK is in the better half of the industry, outperforming 79.27% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for TAK is significantly below the industry average of 13.06%.
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROIC 2.32%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
TAK Yearly ROA, ROE, ROICTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

1.3 Margins

  • TAK's Profit Margin of 2.53% is amongst the best of the industry. TAK outperforms 81.35% of its industry peers.
  • In the last couple of years the Profit Margin of TAK has grown nicely.
  • The Operating Margin of TAK (10.76%) is better than 82.38% of its industry peers.
  • TAK's Operating Margin has improved in the last couple of years.
  • TAK has a Gross Margin of 65.33%. This is in the better half of the industry: TAK outperforms 74.09% of its industry peers.
  • TAK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
TAK Yearly Profit, Operating, Gross MarginsTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TAK Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TAK is creating some value.
  • TAK has more shares outstanding than it did 1 year ago.
  • TAK has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, TAK has an improved debt to assets ratio.
TAK Yearly Shares OutstandingTAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
TAK Yearly Total Debt VS Total AssetsTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T

2.2 Solvency

  • Based on the Altman-Z score of 1.24, we must say that TAK is in the distress zone and has some risk of bankruptcy.
  • TAK has a Altman-Z score (1.24) which is in line with its industry peers.
  • The Debt to FCF ratio of TAK is 6.48, which is on the high side as it means it would take TAK, 6.48 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 6.48, TAK belongs to the best of the industry, outperforming 81.87% of the companies in the same industry.
  • A Debt/Equity ratio of 0.56 indicates that TAK is somewhat dependend on debt financing.
  • The Debt to Equity ratio of TAK (0.56) is worse than 63.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Altman-Z 1.24
ROIC/WACC1.42
WACC1.63%
TAK Yearly LT Debt VS Equity VS FCFTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2T 4T 6T

2.3 Liquidity

  • TAK has a Current Ratio of 1.19. This is a normal value and indicates that TAK is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.19, TAK is doing worse than 77.72% of the companies in the same industry.
  • A Quick Ratio of 0.65 indicates that TAK may have some problems paying its short term obligations.
  • TAK has a worse Quick ratio (0.65) than 84.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.65
TAK Yearly Current Assets VS Current LiabilitesTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500B 1T 1.5T 2T 2.5T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TAK Growth Analysis

3.1 Past

  • TAK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.17%.
  • Measured over the past years, TAK shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.20% on average per year.
  • TAK shows a decrease in Revenue. In the last year, the revenue decreased by -2.50%.
  • Measured over the past years, TAK shows a small growth in Revenue. The Revenue has been growing by 6.84% on average per year.
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%

3.2 Future

  • TAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.92% yearly.
  • The Revenue is expected to grow by 0.20% on average over the next years.
EPS Next Y74.57%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
EPS Next 5YN/A
Revenue Next Year-1.2%
Revenue Next 2Y-0.15%
Revenue Next 3Y0.2%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TAK Yearly Revenue VS EstimatesTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
TAK Yearly EPS VS EstimatesTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

6

4. TAK Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 77.87 indicates a quite expensive valuation of TAK.
  • TAK's Price/Earnings ratio is a bit cheaper when compared to the industry. TAK is cheaper than 77.72% of the companies in the same industry.
  • TAK is valuated expensively when we compare the Price/Earnings ratio to 24.88, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 30.59, TAK can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, TAK is valued a bit cheaper than the industry average as 72.02% of the companies are valued more expensively.
  • TAK's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.19.
Industry RankSector Rank
PE 77.87
Fwd PE 30.59
TAK Price Earnings VS Forward Price EarningsTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • TAK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. TAK is cheaper than 87.05% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, TAK is valued cheaply inside the industry as 88.08% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.06
EV/EBITDA 10.67
TAK Per share dataTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • TAK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of TAK may justify a higher PE ratio.
  • TAK's earnings are expected to grow with 45.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.04
PEG (5Y)4.06
EPS Next 2Y65.4%
EPS Next 3Y45.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. TAK Dividend Analysis

5.1 Amount

  • TAK has a Yearly Dividend Yield of 3.47%. Purely for dividend investing, there may be better candidates out there.
  • TAK's Dividend Yield is rather good when compared to the industry average which is at 0.79. TAK pays more dividend than 94.82% of the companies in the same industry.
  • TAK's Dividend Yield is rather good when compared to the S&P500 average which is at 1.90.
Industry RankSector Rank
Dividend Yield 3.47%

5.2 History

  • The dividend of TAK has a limited annual growth rate of 1.18%.
  • TAK has paid a dividend for at least 10 years, which is a reliable track record.
  • TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
TAK Yearly Dividends per shareTAK Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 50 100 150

5.3 Sustainability

  • TAK pays out 277.04% of its income as dividend. This is not a sustainable payout ratio.
  • The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP277.04%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
TAK Yearly Income VS Free CF VS DividendTAK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B
TAK Dividend Payout.TAK Dividend Payout, showing the Payout Ratio.TAK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

TAK Fundamentals: All Metrics, Ratios and Statistics

TAKEDA PHARMACEUTIC-SP ADR

NYSE:TAK (3/27/2026, 8:04:00 PM)

After market: 17.92 +0.01 (+0.06%)

17.91

-0.15 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners47.91%
Inst Owner Change-0.91%
Ins OwnersN/A
Ins Owner Change0%
Market Cap56.58B
Revenue(TTM)4.46T
Net Income(TTM)112.93B
Analysts74.74
Price Target18.18 (1.51%)
Short Float %0.22%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield 3.47%
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP277.04%
Div Incr Years2
Div Non Decr Years3
Ex-Date03-30
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-121.92%
Max EPS beat(2)90.61%
EPS beat(4)2
Avg EPS beat(4)-2.37%
Min EPS beat(4)-121.92%
Max EPS beat(4)90.61%
EPS beat(8)4
Avg EPS beat(8)-37%
EPS beat(12)6
Avg EPS beat(12)-26.29%
EPS beat(16)8
Avg EPS beat(16)-33.22%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.04%
Max Revenue beat(2)0.21%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)0.21%
Revenue beat(8)4
Avg Revenue beat(8)1.91%
Revenue beat(12)7
Avg Revenue beat(12)2.79%
Revenue beat(16)11
Avg Revenue beat(16)3.3%
PT rev (1m)3.21%
PT rev (3m)11.85%
EPS NQ rev (1m)-82.66%
EPS NQ rev (3m)-28.82%
EPS NY rev (1m)0.17%
EPS NY rev (3m)-11.2%
Revenue NQ rev (1m)1.72%
Revenue NQ rev (3m)2.93%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE 77.87
Fwd PE 30.59
P/S 2.02
P/FCF 12.06
P/OCF 7.6
P/B 1.18
P/tB N/A
EV/EBITDA 10.67
EPS(TTM)0.23
EY1.28%
EPS(NY)0.59
Fwd EY3.27%
FCF(TTM)1.48
FCFY8.29%
OCF(TTM)2.36
OCFY13.17%
SpS8.85
BVpS15.16
TBVpS-3.22
PEG (NY)1.04
PEG (5Y)4.06
Graham Number8.86
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROCE 3.75%
ROIC 2.32%
ROICexc 2.47%
ROICexgc 10.72%
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
FCFM 16.77%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
ROICexc(3y)2.79%
ROICexc(5y)2.75%
ROICexgc(3y)14.77%
ROICexgc(5y)14.24%
ROCE(3y)4.3%
ROCE(5y)4.17%
ROICexgc growth 3Y-5.18%
ROICexgc growth 5Y8.79%
ROICexc growth 3Y-2.83%
ROICexc growth 5Y11.44%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Debt/EBITDA 3.48
Cap/Depr 58.95%
Cap/Sales 9.86%
Interest Coverage 4.11
Cash Conversion 96.87%
Profit Quality 663%
Current Ratio 1.19
Quick Ratio 0.65
Altman-Z 1.24
F-Score5
WACC1.63%
ROIC/WACC1.42
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
EPS Next Y74.57%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
Revenue Next Year-1.2%
Revenue Next 2Y-0.15%
Revenue Next 3Y0.2%
Revenue Next 5YN/A
EBIT growth 1Y0.22%
EBIT growth 3Y0.56%
EBIT growth 5Y14.13%
EBIT Next Year436.14%
EBIT Next 3Y77.24%
EBIT Next 5YN/A
FCF growth 1Y680.23%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y62.56%
OCF growth 3Y-2%
OCF growth 5Y9.54%

TAKEDA PHARMACEUTIC-SP ADR / TAK Fundamental Analysis FAQ

What is the fundamental rating for TAK stock?

ChartMill assigns a fundamental rating of 5 / 10 to TAK.


What is the valuation status for TAK stock?

ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.


What is the profitability of TAK stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for TAK stock?

The Price/Earnings (PE) ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 77.87 and the Price/Book (PB) ratio is 1.18.


How financially healthy is TAKEDA PHARMACEUTIC-SP ADR?

The financial health rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 3 / 10.